We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

NaTiV3 Study

Study Evaluating Long-Term Efficacy And Safety Of Lanifibranor In Adult Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) And Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage Of Liver Fibrosis

diseased liver
AGE: 18+ years old
TYPE: Investigational Drug Study
CONDITION: NASH - Nonalcoholic Steatohepatitis
LOCATION: UH Cleveland Medical Center

Learn More

For more information, please contact the study coordinator, Antonio Levert at 216-286-7069 or complete the online form below.

Study Purpose

The purpose of this research study is to evaluate if the study investigational medication improves your liver tissue scars (fibrosis) and resolves NASH. The study will also evaluate on the long term if the study medication can delay the complications that can ultimately damage the liver function (NASH disease progression).

Who Can Participate

Participants 18 years and older with a diagnosis of NASH may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot